{
    "clinical_study": {
        "@rank": "1360", 
        "acronym": "PEARS-POST", 
        "arm_group": [
            {
                "arm_group_label": "Karinat", 
                "arm_group_type": "Active Comparator", 
                "description": "Karinat 500 mg tablet by mouth three times a day"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 500 mg tablet by mouth three times a day"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the anti-atherosclerotic action of natural drug\n      Karinat based on phytoestrogen-rich botanicals in postmenopausal women."
        }, 
        "brief_title": "Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Atherosclerosis", 
        "condition_browse": {
            "mesh_term": "Atherosclerosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women at least 5 years after menopause\n\n          -  Maximum intima-media thickness of common carotid artery more than 0,80 mm\n             (ultrasonographic B-mode examination)\n\n          -  The absence of climacteric syndrome (less than 3 points by Blatt-Kupperman scale)\n\n          -  The absence of chronic diseases demanding permanent drug administration (more than 2\n             month per year)\n\n          -  The absence of hypolipidemic therapy or hormone replacement therapy during 6 months\n             before the inclusion\n\n        Exclusion Criteria:\n\n          -  Administration of lipid-lowering drugs, and/or hormone replacement therapy, and/or\n             phytoestrogens during 6 month before inclusion\n\n          -  Continuous administration of sulfonylurea derivatives, and/or beta-blockers, and/or\n             calcium antagonists (more than 2 months per year)\n\n          -  Personal history or diagnostic of following diseases:\n\n               1. Personal history of stroke, coronary heart disease, acute myocardial infarction\n                  or transient ischemic attacks\n\n               2. Pulmonary thromboembolism\n\n               3. Chronic heart failure IIa-III\n\n               4. Uncontrolled arterial hypertension (systolic blood pressure > 145 mmHg,\n                  diastolic blood pressure > 95 mmHg under hypotensive therapy)\n\n               5. Malignancy\n\n               6. Chronic renal failure II-III\n\n               7. Chronic hepatic failure II-III\n\n               8. Liver cirrhosis\n\n               9. Individual intolerance of Karinat or major side effects"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742000", 
            "org_study_id": "IAR-KT-POST"
        }, 
        "intervention": [
            {
                "arm_group_label": "Karinat", 
                "intervention_name": "Karinat", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "description": "Sugar pill manufactured to mimic Karinat 500 mg tablet", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "postmenopause", 
            "phytoestrogen", 
            "atherosclerosis", 
            "intima-media thickness"
        ], 
        "lastchanged_date": "December 4, 2012", 
        "number_of_arms": "2", 
        "official_title": "Double-blinded Placebo-controlled Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Variation of intima-media thickness of common carotid arteries", 
            "measure": "B-mode ultrasound of carotid arteries", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742000"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change of the ability of serum to induce cholesterol accumulation in cultured cells", 
            "measure": "Measure of serum atherogenicity", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2 years"
        }, 
        "source": "Institute for Atherosclerosis Research, Russia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute for Atherosclerosis Research, Russia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}